Intratracheal Instillation of Budesonide-Surfactant for Prevention of Bronchopulmonary Dysplasia in Extremely Premature Infants.

Kalsang DolmaMichael ZayekAayushka GurungFabien Eyal

Published in: American journal of perinatology (2023)

· Intratracheal budesonide-surfactant therapy reduces BPD in preterm infants weighing ≥750 grams.. · Intratracheal budesonide-surfactant therapy does not affect BPD in preterm infants weighing <750 grams.. · Intratracheal budesonide-surfactant therapy does not affect the mortality rate in preterm infants..

Keyphrases

preterm infants
low birth weight
cardiovascular events
type diabetes
cardiovascular disease
stem cells
coronary artery disease
bone marrow
cell therapy